Answers are grounded in this paper and cite their sources.
Preclinical trial demonstrated STSA-1002 reduced inflammatory markers in ARDS models, suggesting a potential therapeutic approach.
The complement-activated product (C5a) is a key mediator in the pathogenesis of acute respiratory distress syndrome (ARDS). While blocking C5a represents a promising therapeutic strategy, novel anti-C5a therapies require further development. This study aimed to develop a novel, human anti-C5a monoclonal antibody (STSA-1002) and evaluate its efficacy in treating ARDS through in vitro and vivo studies. In vitro, STSA-1002 exhibited high binding affinity to human and rhesus monkey C5a (EC50: 29.41 ± 10.74 ng/mL and 32.29 ± 10.96 ng/mL, respectively) and effectively inhibited C5a-induced neutrophil degranulation, chemotaxis, and CD11b expression. In vivo, single intravenous administration of STSA-1002 (1, 3 and 10 mg/kg) significantly reduced the levels of interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), granulocyte-macrophage colony stimulating factor (GM-CSF), monocyte chemotactic protein-1 (MCP-1) and mortality in a COVID-19-related LPS-induced ARDS mouse model (Model 1). In a second LPS-induced ARDS model (Model 2), STSA-1002 (1, 5 and 25 mg/kg) significantly reduced IL-6, TNF-α concentrations and leukocyte counts in serum and diminished IL-6 in bronchoalveolar lavage fluid (BALF), alongside improvements in lung weight index. In addition, pharmacokinetic (PK) studies in rhesus monkeys demonstrated linear exposure (5-50 mg/kg) and a favorable safety profile in a 4-week repeat-dose toxicity study. These results furnish comprehensive preclinical evidence for STSA-1002 as an innovative anti-C5a therapeutic agent and provide a preliminary rationale for developing immunomodulatory therapy in ARDS.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: